






FORM – A

(for audit report with unmodified opinion)

(Pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015)

1.	Name of the Company:	SUVEN LIFE SCIENCES LIMITED
2.	Annual financial statements for the year ended	31st March 2016 (Standalone and Consolidated)
3.	Type of Audit observation	Un-modified
4.	Frequency of observation	Not Applicable
5.	<div style="text-align: center;"><p><i>Signed by-</i></p><div style="display: flex; justify-content: space-around;"><div style="text-align: center;"><p>For Suven Life Sciences Limited</p><p>Venkateswarlu Jasti Chairman & CEO DIN: 00278028</p></div><div style="text-align: center;"><p>For Suven Life Sciences Limited</p><p>D G Prasad Chairman of Audit Committee DIN: 00160408</p></div></div><div style="text-align: center;"></div><div style="display: flex; justify-content: space-around; margin-top: 20px;"><div style="text-align: center;"><p>For Suven Life Sciences Limited</p><p>P. Subba Rao Chief Financial Officer M. No. A11342</p></div><div style="text-align: center;"><p>For KARVY & Co., Chartered Accountants FRN: 01757S</p><p>K. AJAY KUMAR Partner M. No. 021989</p></div></div></div>	

Place: Hyderabad

Date: 27th May, 2016

CS/BSE/NSE/AR/2016-2017

July 16, 2016

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

To
The General Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

Stock Code: SUVEN - EQ

Stock Code: 530239

Dear Sir/Madam,


Sub: Furnishing of 27th Annual Report 2015-16 under Regulation 34 of the SEBI (LODR) Regulations, 2015.

.....

With reference to the above subject, as per Regulation 34 of the SEBI ((Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the 27th Annual Report 2015-16 which includes Directors' Report, Balance Sheet, Statement of Profit & Loss and cash flow statement. This is for your information and records.

Kindly acknowledge the receipt of the same.


Thanking You,
Yours faithfully,
For **Suven Life Sciences Limited**



K. Hanumantha Rao
Company Secretary

Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com



SUVN LIFE SCIENCES LIMITED | 27TH ANNUAL REPORT
2015-16

PUTTING IT ALL
TOGETHER

CAUTIONARY STATEMENT

In this Annual Report, we have disclosed forward-looking information to enable investors to comprehend our prospects and take informed investment decisions. This report and other statements - written and oral - that we periodically make contain forward-looking statements that set out anticipated results based on the management's plans and assumptions. We have tried, wherever possible, to identify such statements by using words such as 'anticipates', 'estimates', 'expects', 'projects', 'intends', 'plans', 'believes', and words of similar substance in connection with any discussion of future performance.

We cannot guarantee that these forward-looking statements will be realised, although we believe we have been prudent in assumptions. The achievement of results is subject to risks, uncertainties and even

inaccurate assumptions. Should known or unknown risks or uncertainties materialise, or should underlying assumptions prove inaccurate, actual results could vary materially from those anticipated, estimated or projected. Readers should bear this in mind.

We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.



SUVEN LIFE SCIENCES LIMITED.

RESEARCH-FOCUSED PHARMACEUTICAL PLAYER. WORKING COLLABORATIVELY WITH GLOBAL INNOVATOR COMPANIES.

STRENGTHENING ITS BUSINESS; ENHANCING NATIONAL RESPECT; HELPING MANKIND COUNTER DISEASE.



CONTENTS

06 - ABOUT SUVEN	08 - WHAT SUVEN ACHIEVED IN 2015-16
10 - 10 MINUTES WITH THE CHAIRMAN	
14 - OPERATIONAL OVERVIEW	16 - MANAGEMENT DISCUSSION AND ANALYSIS
24 - BOARD'S REPORT	
52 - REPORT ON CORPORATE GOVERNANCE	
65 - STANDALONE FINANCIAL SECTION	
95 - CONSOLIDATED FINANCIAL SECTION	

Total CRAMS projects delivered
Until 31 March 2016

755

Relationships with global
pharmaceutical companies
As on 31 March 2016

57

Percentage of income from
regulated pharmaceutical markets
In 2015-16

87

Research team
As on March 31, 2016

385

R&D investment as a
proportion of net revenues
In 2015-16

12%

Revenue from operations (₹ crore)
In 2015-16

500

Net profit (₹ crore)
In 2015-16

95

Net worth (₹ crore)
As on 31 March 2015-16

624

Total Debt (₹ crore)
As on 31 March 2015-16

84

Suven Life Sciences Limited pioneered the NCE-based CRAMS space in India.

A challenging space. A dynamic space. An unpredictable space. This is what we have to show for our success.

Robust business relationships with 20+ global innovators

Successful track record of 755+ projects

Delivery of more than 95% projects on schedule

Generated pre-R&D EBIDTA margin in excess of 25% over the last five years

Reinforced leadership in our business niche





TRANSFORMING OUR
CRAMS VERTICAL

FROM THE UNPREDICTABLE TO THE STABLE

Even as we have grown our revenues by 152% in the five years ending 2015-16, there is an apprehension that the high-risk NCE-based CRAMS space is not predictable, as Suven's successful project delivery does not guarantee repeat business and an innovator client can terminate molecule development.

For all the pessimists, we have a message.

After two decades of passionate engagement in the CRAMS space, Suven is at the cusp of transforming an unpredictable business towards increased stability.

We believe that this transformation will become increasingly manifest for some good reasons.

Commercial volumes for molecule launches: We supplied pre-launch quantities of intermediates for three molecules pertaining to three therapeutic indications – rheumatoid arthritis for a US-based innovator, anti-depressant and an anti-diabetic for European innovators. The commercial volumes for these products are expected to commence in 2016-17 and continue over the next few years.



Intermediate for specialty chemicals: We supply a complex speciality intermediary (derived from our CRAMS competence). The sales volume of this intermediate strengthened by 40% in 2015-16 and we expect to maintain similar volumes over the next few years.

ANDAs: In addition to the exclusive marketing license for our Malathion lotion to Taro Pharmaceuticals for the US and Canada, we filed three ANDAs in collaboration with customers; the maturing of these ANDAs could lead to attractive revenues.

Stable revenues from speciality chemicals and commercial supplies could lead to annuity revenues and topline growth of about 10-15%, reducing income volatility and providing stability.

3

We filed three ANDAs in collaboration with customers; the maturing of these ANDAs could lead to attractive revenues.



GRADUATING OUR
NCE INITIATIVE

FROM HIGH-RISK TO HIGH-RETURN



Even as our innovative pipeline received 984 product patents for 28 inventions and 38 process patents for 8 inventions, there is a lurking worry about the pace of our NCE development.

The fears are not misplaced. Of every 100 candidates initiated for clinical development the world over, only one on average succeeds to fruition.

At Suven, we possess a stronger average. Three of our NCE candidates moved into advanced stages in the molecule development lifecycle, making their prospective monetisation an increasing possibility.

Our flagship candidate SUVN 502 initiated phase 2A study in USA under US-IND and expected completion by last quarter of 2017.

Our SUVN-G3031 candidate completed Phase 1 trials in USA under US-IND successfully, undergoing long-term toxicology studies prior to entering Phase 2 trials.


Our SUVN-D4010 candidate completed Phase 1 clinical trials in USA under US-IND and will enter into long-term toxicological studies to move into Phase 2 clinical trial.

Our SUVN-911 candidate is in preparation for entering into Phase 1 clinical trials.

Even as per conservative estimates, the successful monetisation of even a single molecule has the potential to significantly advance business prospects (financially) and respect (globally).

25

Planned investment (US\$, mn) by Suven in developing SUVN 502 through Suven, Inc., for Phase 2A clinical development program in USA.






ABOUT THE
CORPORATE

SUVEN LIFE SCIENCES.
PIONEERED NCE-BASED
CRAMS IN INDIA AND IS A
LEADER IN THIS SPACE.

AMONG THE FEW INDIAN
PHARMACEUTICAL
PLAYERS FOCUSED
ON DEVELOPING NEW
CHEMICAL ENTITIES
IN THE COMPLEX CNS
SPACE.

RESPECTED OUTLIER IN
A HIGH-PROFIT NICHE.

MAKING IT A COMPANY
ATTRACTING GROWING
RESPECT IN THE GLOBAL
RESEARCH-LED
PHARMACEUTICAL
INDUSTRY.



60%

Promoters' holding,
March 31, 2016

7%

Institutional holding,
March 31, 2016

2,452

Market capitalisation,
March 31, 2016
(₹ crore)